Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Jefferson Research
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Halozyme Therapeutics Inc announces positive results from phase 1/2 clinical trial in Cellulite With HTI-501


Tuesday, 25 Mar 2014 08:00am EDT 

Halozyme Therapeutics Inc:Top-line data from proof of concept Phase 1/2 clinical trial evaluating the use of HTI-501 in the treatment of cellulite.Primary endpoint of clinical trial was met, showing statistically significant improvement in appearance of cellulite in areas of patients' skin.Treated with HTI-501 as determined by physician assessment 28 days after treatment compared to same skin areas prior to treatment and skin areas treated with vehicle control.In follow up, effect, as assessed by physician assessment, was maintained at three and six months. 

Company Quote

9.75
-0.13 -1.32%
3:29pm EDT